Clinical-stage developer of an antibody-based theranostic that targets GPC-1 on solid tumors (prostate, bladder, pancreatic, glioblastoma, oesophageal, ovarian) to address high‑unmet‑need cancers. Uses 89Zr for diagnostic imaging to select patients and 177Lu (with preclinical 225Ac/212Pb programs) to deliver targeted radiotherapy; first-in-human trial (12 patients) reported no drug-related adverse events.